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A recent study by Mann et al. [1] published in 
Oncotarget exploits the use of aptamers as a targeting 
ligand  to  develop  site-specific  delivery  of  liposomal 
nanocarriers. It has already been 17 years, since an 
article titled ‘Liposomes revisited’ was published co-
authored by Lasic and Papahadjopoulos [2]. In essence, 
this publication marked the launch of the first success 
story of nanomedicine into the clinic and the beginning 
of  an  entire  field.  However,  this  was  not  an  accident. 
The successful development of sterically stabilized 
liposomes was the product of 30 years of intensive 
research,  since  Bangham  first  discovered  in  the  early 
1960s that phospholipids in water form a vesicle enclosed 
in a bilayered lipid membrane [3, 4]. Not surprisingly, a 
pubmed search of the word ‘liposome’ resulted in 14,858 
articles published between 1965 and 1995. The focus of 
these studies ranged from the in vitro particle stability to 
the effect of size, lipid composition and polymer coating 
of liposomes on their blood circulation, intratumoral 
accumulation and anticancer activity [5-7]. Furthermore, 
stable encapsulation of doxorubicin into the liposome 
with negligible leakage of the drug in blood circulation 
was achieved with the remote loading method against 
an  ammonium  sulfate  gradient  [8].  And  finally  voilá: 
a PEGylated unilamellar liposome composed of rigid 
phosphatidylcholine and cholesterol with a diameter of 
about 100 nm displayed prolonged circulation time and 
as a result an increased intratumoral accumulation and 
antitumor activity [6, 7].
So, what is the advantage of a long-circulating 
nanoparticle over conventional chemotherapies? It was 
shown that the therapeutic index of chemotherapeutics 
can be substantially improved, since nanoparticle delivery 
systems exploit a feature of tumor microenvironment, the 
so-called ‘Enhanced Permeability and Retention’ (EPR) 
effect [9]. While potent chemotherapeutic drugs are 
available to oncologists, the systemic dose of these agents 
is constrained by normal tissue tolerance, since these 
agents are distributed within cancer and healthy tissues 
in a non-specific manner. On the other hand, liposomes 
improve the safety profile of drugs due to their localization 
with high specificity in solid tumors while reducing off-
target delivery [10, 11]. This unique feature has led to the 
development of various nanoparticle delivery systems, 
which are under preclinical and clinical evaluation [12]. 
The question that emerges then is: Could this old dog 
learn new tricks? This was promptly answered as it was 
recognized that the key feature of nanoparticles is the 
ability to combine more than one function by enabling the 
design of agents that target, image, and destroy tumors 
[13]. 
To further maximize the specificity towards cancer 
cells, targeting nanoparticles using a receptor-ligand 
system quickly attracted a lot of attention. Initially, 
nanoparticles were decorated with antibodies or small 
molecules that target receptors known to be over-
expressed by tumors. Folate receptor-targeted liposomes 
were one of the first systems to be extensively studied. 
This is an ideal targeting system, since the folate receptor 
is an upregulated transmembrane receptor in various 
tumors [14]. While in vitro studies showed encouraging 
results proving that drugs delivered via folate receptor-
targeted liposomes are rapidly transferred to the nuclei of 
target cells [15], the in vivo performance of these agents 
did not show an improved therapeutic efficacy in terms 
of prolonged survival [16]. Unfortunately, numerous 
studies have shown that the presence of folic acid or 
other targeting ligands (e.g. antibodies) on the surface 
of liposomes compromises their blood circulation time 
[15, 17, 18]. This is not unexpected as long circulation 
time of liposomal nanocarriers is due to a polyethylene 
glycol (PEG) shielding, and when targeting ligands are 
employed, they are usually conjugated on the distal end 
of the PEG chain resulting in recognition by the reticulo-
endothelial system (RES) and accelerated clearance by 
the liver. Due to fact that nanoparticle extravasation is 
directly proportional to their concentration in blood [19], 
fewer targeted particles are able to reach the tumor site 
and consequently the gains from active targeting after 
extravasation into the tumor are compromised [20]. 
To address this major drawback, an elegant trick was 
proposed by McNeeley et al. [14]. A nanoparticle system 
targeting the folate receptor was developed based on a 
detachable PEG mask that ‘buries’ the targeting ligands 
when the nanoparticle is in circulation to maximize 
passive targeting to tumors. This detachable polymer 
coating can be removed by the administration of cysteine 
after nanoparticle extravasation to tumor is achieved to 
expose targeting ligands and promote active targeting 
only to cancer cells.
However, a simpler trick is to search for targeting 
moieties that are not immunogenic. Besides antibodies, 
many  different  types  of  affinity  ligands,  including Oncotarget 2011; 2:  430 - 432 431 www.impactjournals.com/oncotarget
humanized monoclonal antibodies, peptides and 
carbohydrate mimetics, have been developed [21, 22]. 
For  example,  oligopeptides  identified  by  phase  and 
bacterial display have lead to the development of targeted 
nanoparticles with comparable blood circulation as 
their non-targeted counterparts [23]. Aptamers based on 
oligonucleic acids present the most recent advancement 
in the search for high affinity and specificity ligands with 
improved pharmacokinetics and serum stability. Aptamers 
have been shown to mimic protein-binding molecules, 
and yet exhibit high binding affinity and selectivity [24]. 
For example, Pegaptanib is a vascular endothelial growth 
factor  (VEGF)-specific  aptamer  that  binds  to  human 
VEGF with KD of 0.14 nM [25]. In contrast, affinity of 
VEGF neutralizing antibodies that block human VEGF 
binding to VEGFR-2 is about 0.4 nM [26]. Considering 
the  affinity  of  peptides,  a  family  of  VEGF-binding 
peptides can bind to the VEGF receptor with KD ranging 
from 0.14- 10 µM [27, 28]. Thus, the affinity of aptamers 
is very high and comparable to that of antibodies.
The study by Mann et al. [1] demonstrates the 
successful design of an active targeting liposomal 
system  based  on  an  aptamer  ligand.  They  identified  a 
thioated oligonucleotide aptamer (thio-aptamer) that 
binds E-selectin expressed on endothelial cells with high 
affinity  and  specificity.  Liposomes  decorated  with  the 
thio-aptamer on the outer surface exhibited (1) prolonged 
blood circulation that was comparable to the non-targeted 
formulation and (2) binding to tumor vasculature with 
high  specificity.  Thus,  this  work  demonstrates  that 
aptamers are an attractive alternative over antibody or 
peptide ligands based on their biological and chemical 
properties,  such  as  small  size,  high  affinity  binding, 
selectivity, low immunogenicity, slow degradation 
kinetics, and a relatively low cost production process 
[24, 29, 30]. Aptamers are particularly well suited for 
nanotechnology applications, because they can be readily 
modified with functional groups that facilitate conjugation 
to nanomaterials [29]. 
In conclusion, studies like this show that 
nanomedicine has grown from an ‘exotic’ research area 
to  a  mainstream  scientific  field,  which  is  governed  by 
its own distinctive principles in terms of intravascular, 
transvascular and interstitial transport [31, 32]. Besides 
exploiting the multifunctionality of nanotechnology 
to develop targeting therapeutic, imaging and multi-
component agents, the engineerability of nanoparticles 
has led to nanostructures with various shapes [33, 34] and 
new properties [35-37]. Therefore, it can be envisioned 
that the multifunctional and engineerable nature of 
nanotechnology can potentially facilitate agents that 
overcome the tumor biobarriers limiting the systemic 
delivery of active compounds.
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